5-day nonobserved artesunate monotherapy for treating uncomplicated Falciparum malaria in young Gabonese children

Am J Trop Med Hyg. 2005 Oct;73(4):705-9.

Abstract

Despite different recommendations from WHO and national authorities, artesunate monotherapy is increasingly used for treating African children with malaria. A 5-day course of oral artesunate (first day: 4 mg/kg body weight, observed intake; and 2 mg/kg body weight on the following days with nonobserved drug intake) yielded a PCR-corrected Day 28 cure rate of 90% (45 of 50 patients; CI 78-97%) in Gabonese children aged between 2 and 18 months. Artesunate was well tolerated, and no severe adverse events were reported.

Publication types

  • Clinical Trial

MeSH terms

  • Animals
  • Antimalarials / administration & dosage
  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use*
  • Artemisinins / administration & dosage
  • Artemisinins / adverse effects
  • Artemisinins / therapeutic use*
  • Artesunate
  • Female
  • Gabon
  • Humans
  • Infant
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / parasitology
  • Male
  • Parasitemia / drug therapy
  • Parasitemia / parasitology
  • Plasmodium falciparum / classification
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / genetics
  • Sesquiterpenes / administration & dosage
  • Sesquiterpenes / adverse effects
  • Sesquiterpenes / therapeutic use*
  • Treatment Outcome

Substances

  • Antimalarials
  • Artemisinins
  • Sesquiterpenes
  • Artesunate